IPHA revenueFY2025€9.01M
- FY YoY
- -55.2%
- 5Y CAGR
- -33.6%
IPHA revenue was €9.01M for fiscal 2025 (ended Dec 31, 2025), down 55.2% from fiscal 2024. Compound annual growth was -33.6% over 5 years. It rose in 3 of the last 8 fiscal years.
Innate Pharma S.A. ADS (IPHA) financials
For fiscal 2025 (ended Dec 31, 2025), Innate Pharma S.A. ADS reported €9.01M of revenue and -€49.18M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €9.01M
- Revenue growth, YoY
- -55.2%
- Net income, FY2025
- -€49.18M
- Net margin
- -546.1%
- Free cash flow, FY2025
- -€52.90M
- EPS, diluted, FY2025
- -€0.55
- Cash
- €28.09M
FY2017FY2025
FY2017FY2025
FY2017FY2025
IPHA revenue and earnings growth
IPHA net incomeFY2025-€49.18M
IPHA net income was -€49.18M for fiscal 2025 (ended Dec 31, 2025), compared with -€49.47M in fiscal 2024.
IPHA EPSFY2025-€0.55
IPHA diluted EPS was -€0.55 for fiscal 2025 (ended Dec 31, 2025), compared with -€0.61 in fiscal 2024.
IPHA free cash flowFY2025-€52.90M
IPHA free cash flow was -€52.90M for fiscal 2025 (ended Dec 31, 2025), compared with -€7.29M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | €9.01M | €20.12M | €61.64M | €57.67M | €24.70M | €69.77M | €85.45M | €93.95M | €44.03M |
| Research and development | €43.62M | €51.98M | €56.02M | €51.66M | €47.00M | €49.71M | €62.90M | €69.56M | €67.00M |
| Selling, general and admin | €19.39M | €19.72M | €18.29M | €22.44M | €25.52M | €18.99M | €20.98M | €18.14M | €17.02M |
| Operating income | -€54.01M | -€51.58M | -€12.67M | -€57.42M | -€47.83M | €1.08M | €1.57M | €5.15M | -€39.98M |
| Interest expense | €440.0K | €566.0K | €640.0K | €288.0K | €312.0K | €341.0K | €204.0K | €102.0K | €113.0K |
| Pre-tax income | -€49.18M | -€49.47M | -€7.57M | -€57.97M | -€45.48M | -€829.0K | €7.87M | €2.72M | -€48.02M |
| Income tax | €0 | €0 | €0 | €0 | €0 | €0 | €0 | -€333.0K | €368.0K |
| Net income | -€49.18M | -€49.47M | -€7.57M | -€58.10M | -€52.81M | -€63.98M | -€20.76M | €3.05M | -€48.38M |
| EPS, basic | -€0.55 | -€0.61 | -€0.09 | -€0.73 | -€0.66 | -€0.81 | -€0.31 | €0.05 | -€0.89 |
| EPS, diluted | -€0.55 | -€0.61 | -€0.09 | -€0.73 | -€0.66 | -€0.81 | -€0.31 | €0.05 | -€0.89 |
| Diluted shares | 89.6M | 81.1M | 80.5M | 79.6M | 79.5M | 78.9M | 66.9M | 58.8M | 54.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | €28.09M | €66.40M | €70.61M | €84.22M | €103.76M | €136.79M | €202.89M | €152.31M | €99.37M |
| Receivables | €12.40M | €4.97M | €55.56M | €38.35M | €18.42M | €21.81M | €18.74M | €152.11M | €21.41M |
| Current assets | €46.71M | €85.74M | €148.01M | €139.83M | €138.26M | €173.45M | €237.60M | €319.64M | €137.52M |
| Total assets | €62.72M | €111.06M | €175.19M | €199.29M | €267.50M | €307.42M | €401.36M | €451.22M | €255.02M |
| Current liabilities | €36.65M | €32.98M | €39.64M | €41.34M | €79.89M | €45.49M | €121.82M | €196.74M | €73.91M |
| Total liabilities | €84.42M | €102.22M | €123.29M | €145.14M | €160.06M | €151.45M | €183.94M | €284.10M | €155.58M |
| Shareholders' equity | -€21.70M | €8.83M | €51.90M | €54.15M | €107.44M | €155.98M | €217.42M | €167.12M | €99.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -€52.76M | -€6.90M | -€32.56M | -€19.16M | -€58.46M | -€51.77M | €34.92M | -€32.53M | -€48.06M |
| Capital expenditures | €140.0K | €391.0K | €351.0K | €535.0K | €929.0K | €907.0K | €1.27M | €873.0K | €2.96M |
| Free cash flow | -€52.90M | -€7.29M | -€32.91M | -€19.69M | -€59.39M | -€52.67M | €33.65M | -€33.40M | -€51.02M |
| Investing cash flow | €7.29M | €9.20M | €20.63M | €1.88M | -€917.0K | -€13.37M | -€62.12M | €24.28M | -€29.46M |
| Financing cash flow | €6.07M | -€6.01M | -€1.97M | -€1.83M | €26.82M | -€1.18M | €77.77M | €61.22M | €915.0K |
| Stock-based compensation | €2.57M | €3.94M | €4.26M | €4.25M | €2.62M | €2.48M | €3.83M | €2.71M | €9.83M |
| Depreciation and amortization | €1.38M | €1.99M | €5.09M | €45.41M | €4.60M | €56.80M | €16.53M | €7.40M | €4.39M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -55.2% | -67.4% | 6.9% | 133.5% | -64.6% | -18.3% | -9.1% | 113.4% | - |
| Operating margin | -599.8% | -256.3% | -20.6% | -99.6% | -193.6% | 1.5% | 1.8% | 5.5% | -90.8% |
| Net margin | -546.1% | -245.9% | -12.3% | -100.7% | -213.8% | -91.7% | -24.3% | 3.2% | -109.9% |
| Free cash flow margin | -587.4% | -36.2% | -53.4% | -34.1% | -240.4% | -75.5% | 39.4% | -35.6% | -115.9% |
| Return on equity | - | -560.0% | -14.6% | -107.3% | -49.2% | -41.0% | -9.5% | 1.8% | -48.7% |
| Return on assets | -78.4% | -44.5% | -4.3% | -29.2% | -19.7% | -20.8% | -5.2% | 0.7% | -19.0% |
| Current ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 | 3.81 | 1.95 | 1.62 | 1.86 |
Source: XBRL data Innate Pharma S.A. ADS files with the SEC, latest filing dated Apr 1, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
IPHA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IPHA | €9.01M | -55.2% | -€49.18M | -546.1% | $160.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
IPHA FAQ
8 questionsWhat is IPHA revenue?
Innate Pharma S.A. ADS (IPHA) reported €9.01M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 55.2% from the year before.Is IPHA profitable?
No. Innate Pharma S.A. ADS reported a net loss of €49.18M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does IPHA have?
Innate Pharma S.A. ADS reported €28.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is IPHA revenue growing?
Innate Pharma S.A. ADS's revenue changed -55.2% in fiscal 2025, to €9.01M. Its compound annual growth rate was -33.6% over 5 years.What is IPHA free cash flow?
Innate Pharma S.A. ADS generated -€52.90M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€52.76M less capital expenditures.What is IPHA earnings per share?
Diluted earnings per share were -€0.55 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did IPHA last report financial results?
The latest statements here come from Innate Pharma S.A. ADS's 20-F filed on Apr 1, 2026, covering the period ended Dec 31, 2025.Where does this IPHA financial data come from?
Quantisnow builds these statements from the structured XBRL data Innate Pharma S.A. ADS files with the SEC. It is provided for information only and is not investment advice.